CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0459 (clinicaltrials.gov NCT No: NCT02129062)
Title:A Phase 2 Study to determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients with Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)
Principal Investigator:Jan A. Burger
Treatment Agent:Ibrutinib
Study Status:Open
Study Description:The purpose of this study is to evaluate the effectiveness of ibrutinib in
patients with relapsed or refractory B-ALL as measured by objective response
rate. The safety of ibrutinib in patients with relapsed or refractory B-ALL
will be studied. The response duration will be assessed . The Bruton’s
Tyrosine Kinase (BTK) target inhibition, biomarkers, and gene expression
profiles in B-ALL patient will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ibrutinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:National Cancer Institute (NCI)
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jan A. Burger
Dept:Leukemia
For Clinical Trial Enrollment:713-792-8165
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults